Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 757-763

  Göstring, Lovisa ^a,b   Chew, Ming Tsuey ^a   Orlova, Anna ^a,b   Höidén Guthenberg, Ingmarie ^b   Wennborg, Anders ^b   Carlsson, Jörgen ^a   Frejd, Fredrik Y ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

Author keywords

A431; Affibody molecule; Alexa488; Cetuximab; CypHer5E; EGFR; Internalization; Radionuclide; Retention

Indexed keywords

CETUXIMAB; DIMER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOMER; RADIOISOTOPE;

ALEXA488 FLUORESCENCE; ARTICLE; CELL ASSAY; CHEMICAL LABELING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYPHER FLUORESCENCE; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; INTERNALIZATION; METHODOLOGY; PHOTOCHEMICAL QUENCHING; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SQUAMOUS CELL CARCINOMA;

BIOLOGICAL TRANSPORT; CARBOCYANINES; CELL LINE, TUMOR; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; INDIUM RADIOISOTOPES; KINETICS; LIGANDS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SUCCINIMIDES;

EID: 77749333043     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000551     Document Type: Article

References (32)

1. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
2. Vincenzi B, Schiavon G, Silletta M, Santini D and Tonini G: The biological properties of cetuximab. Crit Rev Oncol Hematol 68: 93-106, 2008.
3. Burden S and Yarden Y: Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847-855, 1997.
4. Ushiro H and Cohen S: Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 255: 8363-8365, 1980.
5. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
6. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
7. Sorkin A, Krolenko S, Kudrjavtceva N, Lazebnik J, Teslenko L, Soderquist AM and Nikolsky N: Recycling of epidermal growth factor-receptor complexes in A431 cells: identification of dual pathways. J Cell Biol 112: 55-63, 1991.
8. Carpentier JL, White MF, Orci L and Kahn RC: Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells. J Cell Biol 105: 2751-2762, 1987.
9. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP and Polo S: Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102: 2760-2765, 2005.
10. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M and Nygren PA: Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15: 772-777, 1997.
11. Nilsson FY and Tolmachev V: Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10: 167-175, 2007.
12. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Hoiden-Guthenberg I, Widstrom C, Carlsson J, Tolmachev V, Stahl S and Nilsson FY: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66: 4339-4348, 2006.
13. Ekblad T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L, Wennborg A, Karlstrom AE and Tolmachev V: Development and preclinical characterisation of (99m)Tc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35: 2245-2255, 2008.
14. Baum R, Orlova A, Tolmachev V and Feldwisch J: A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an indium-111-or Gallium-68-labeled Affibody molecule. Eur J Nucl Med Mol Imaging 33: S91, 2006.
15. Friedman M, Orlova A, Johansson E, Eriksson TL, Hoiden-Guthenberg I, Tolmachev V, Nilsson FY and Stahl S: Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 376: 1388-1402, 2008.
16. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, Hodik M, Stahl S, Frejd FY and Orlova A: Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50: 274-283, 2009.
17. Beletskii A, Cooper M, Sriraman P, Chiriac C, Zhao L, Abbot S and Yu L: High-throughput phagocytosis assay utilizing a pH-sensitive fluorescent dye. Biotechniques 39: 894-897, 2005.
18. Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, Nilsson FY, Stahl S, Glimelius B and Carlsson J: Cellular studies of binding, internalization and retention of a radio-labeled EGFR-binding affibody molecule. Nucl Med Biol 34: 609-618, 2007.
19. Steffen AC, Gostring L, Tolmachev V, Palm S, Stenerlow B and Carlsson J: Differences in radiosensitivity between three HER2 overexpressing cell lines. Eur J Nucl Med Mol Imaging 35: 1179-1191, 2008.
20. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J and Scheller RH: Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282, 2004.
21. Sklar LA, Oades ZG, Jesaitis AJ, Painter RG and Cochrane CG: Fluoresceinated chemotactic peptide and high-affinity anti-fluorescein antibody as a probe of the temporal characteristics of neutrophil stimulation. Proc Natl Acad Sci USA 78: 7540-7544, 1981.
22. Sorkin A and Goh LK: Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315: 683-696, 2009.
23. Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A and O'Connor McCourt M: Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 312: 2778-2790, 2006.
24. Gronwall C, Jonsson A, Lindstrom S, Gunneriusson E, Stahl S and Herne N: Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J Biotechnol 128: 162-183, 2007.
25. Gunneriusson E, Nord K, Uhlen M and Nygren P: Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng 12: 873-878, 1999.
26. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J and Stahl S: Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20: 189-199, 2007.
27. Renberg B, Shiroyama I, Engfeldt T, Nygren PK and Karlstrom AE: Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. Anal Biochem 341: 334-343, 2005.
28. 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 19: 853-857, 2008.
29. Vernet E, Konrad A, Lundberg E, Nygren PA and Graslund T: Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. J Immunol Methods 338: 1-6, 2008.
30. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M, Nilsson FY, Wennborg A, Abrahmsen L and Feldwisch J: Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67: 2178-2186, 2007.
31. Wallberg H and Orlova A: Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23: 435-442, 2008.
32. Fan Z, Lu Y, Wu X and Mendelsohn J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595-27602, 1994.